The Cupid Ltd Story: How a Small-Cap Condom Maker Became a Multibagger
Every few years, the Indian market throws up a small-cap story that leaves everyone slightly bewildered. Cupid Ltd, a Nashik-based manufacturer of male and female condoms and personal lubricant sachets, is one of those stories. Between early 2023 and late 2025, the stock more than quadrupled. It went from a barely-covered ₹500 crore market-cap company to a name that even taxi drivers in Mumbai suddenly wanted to talk about.
If you missed the rally, that's a normal experience — most small-cap runs happen while nobody is paying attention. But the story of why Cupid worked is genuinely instructive, especially if you are learning how to think about mid- and small-cap investing in India. This is a case study, not a stock recommendation.
The company nobody was watching
Cupid was set up in 1993 by Omprakash Garg. For the first two decades of its life, it did what most Indian mid-tier manufacturers do: it survived. Revenue crawled along in the ₹40-60 crore range. The stock traded at throwaway valuations. Coverage was almost non-existent — you would struggle to find a serious brokerage report on the company before 2020.
The business was straightforward. Cupid manufactured male condoms, female condoms and lubricant sachets, primarily for institutional tenders — the WHO (via the UNFPA), the government of South Africa, the Brazilian ministry of health, and several other public-health procurement bodies across Africa and Latin America. It was not a consumer brand story. It was a bidding-and-fulfilling story, and it moved with the rhythm of global tenders.
The company had one genuinely rare capability. It was one of only two players in the world with WHO pre-qualification for the female condom — a niche, low-volume, high-margin product. That single fact would eventually turn out to matter a lot.
Why 2023 was the turning point
Three things happened between late 2022 and mid-2023 that changed the arithmetic entirely.
A promoter change. In November 2022, an SPV led by investor Aditya Halwasia and businessman Om Prakash Garg's family agreed to a promoter transition. The new management, with a background in capital markets, brought a very different mindset — quarterly investor calls, an actual investor-relations function, and clearer capital-allocation targets. For a company that had spent decades avoiding the spotlight, this was a jolt.
A capacity expansion plan. Cupid announced a doubling of its condom-manufacturing capacity, funded largely from internal accruals. The Nashik plant, which had been running near full utilisation for years, would nearly triple in capability. The company also signalled entry into the domestic Indian consumer market — historically dominated by Manforce, Kohinoor and Durex.
A step-up in tender wins. Between 2023 and 2025, Cupid secured a run of large orders from South Africa, Brazil and the UNFPA. The order book, which had rarely exceeded ₹100 crore, crossed ₹350 crore. Revenue growth suddenly went from single digits to 40%-plus.
None of these were secret. All three were disclosed. But small-cap coverage in India is thin, and it takes time for institutional money to notice. By the time it did, in mid-2024, the stock had already doubled.
What the multibagger arithmetic actually looked like
For anyone learning how a re-rating happens, Cupid is a textbook case. Break the return into three components.
Earnings growth. Standalone profit went from around ₹22 crore in FY22 to over ₹55 crore in FY24 and continued higher into FY25. Roughly 2.5x growth in earnings in three years.
Multiple expansion. The market's willingness to pay for those earnings changed dramatically. Cupid used to trade at 12-15x earnings — the standard "small-cap discount" multiple. As management delivered on promises, the multiple expanded to 40x+ at the peak. Roughly another 2.5x from valuation.
Sentiment overlay. Once the stock had run, retail investors piled in. Small-cap PMS managers started building positions. Everyone wanted a "structural" story in personal healthcare. This is the least fundamental part of the return, but in Indian small caps it is often the biggest.
Multiply those factors together and you get the six-to-seven-times return the stock delivered from its 2022 base. Very little of it required believing anything dramatic about the business. It just required the market to notice.
The uncomfortable truths
Before anyone reads this and rushes to buy the next Cupid, some plain-speak is important.
The business is still tender-driven. Roughly 70-80% of Cupid's revenue depends on a small number of government and multilateral procurement contracts. If South Africa delays a tender by two quarters, the P&L takes a visible hit. This is not the same risk profile as a consumer FMCG company.
The domestic consumer play is unproven. Cupid has announced it will build a branded presence in India. Anyone who has watched Reckitt Benckiser (Durex) or Mankind (Manforce) will tell you this is not a market you enter cheaply. Advertising, distribution, chemist relationships — the entry costs are large and the incumbents are entrenched.
Small-cap volatility cuts both ways. In the two market corrections of 2024-25, Cupid dropped 25-30% inside a month, more than once. If you cannot sit through that kind of drawdown without panicking, small-cap investing is not for you regardless of the story.
The lessons for retail investors
Cupid is worth studying not because you should buy it, but because it illustrates how multi-baggers actually happen in India.
They usually hide in plain sight for years. The people who made 5-10x on Cupid were not first-in. They were people who had held for four or five years while the stock did almost nothing, then got rewarded when management and market conditions finally aligned.
Corporate events matter more than "themes". The single biggest catalyst here was the promoter change, not any macro thesis about India's healthcare consumption. Track annual reports, board changes and capex announcements more than you track TV panels.
Small caps re-rate fast and de-rate faster. Multiples can go from 12x to 40x in twenty-four months. They can also come back to 20x in six. Never anchor your fair-value estimate to the peak multiple.
Position sizing is everything. A 2% position that becomes a 6-bagger changes your portfolio. A 25% position in the same stock that then draws down 40% can end an investing career. Even the best small-cap ideas belong in small allocations, at least until they prove themselves as mid-caps.
Where does the story go from here
At the time of writing, Cupid trades at a market capitalisation of roughly ₹2,500-3,000 crore, still small by Nifty 50 standards but no longer a hidden name. The next twelve to eighteen months will decide whether it re-rates further or consolidates.
Three questions matter. Will the announced domestic consumer launch actually gain traction against Manforce and Durex? Will the female condom order book grow as African health budgets recover post the aid-cut cycle of 2024-25? And can the company translate its capacity expansion into sustained 25%-30% earnings growth, or will growth normalise to 12-15% as the base rises?
The market will find out. If the answers are broadly yes, Cupid becomes a mid-cap. If they are no, it goes back to being a story stock that had one great re-rating. Either outcome is possible, which is exactly what makes small-cap investing hard.
The takeaway
The Cupid rally was not a fluke, and it was not a scam. It was the ordinary mechanics of the Indian small-cap market playing out in a compressed timeframe — a genuine operational turnaround, a promoter change, a run of tender wins, and a delayed rediscovery by institutional investors.
If you learn one thing from the story, let it be this: the biggest returns in Indian equity markets rarely come from the most talked-about names. They come from the companies that spent a decade being ignored, then quietly delivered two years of clean execution while nobody was looking.
This article is educational. It is not investment advice. Please do your own due diligence and consider consulting a SEBI-registered advisor before making decisions.